Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Vismodegib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 10 Aug 2017 Planned primary completion date changed from 30 Jun 2017 to 1 Aug 2020.
- 10 Aug 2017 Status changed from suspended to recruiting.
- 11 Jan 2017 Status changed from recruiting to suspended.